Cargando…

OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients

BACKGROUND: Osteoporosis is a common comorbidity in patients with cystic fibrosis (CF); malabsorption, chronic glucocorticoid use, and chronic inflammation all contribute to increased bone resorption and decreased bone formation. Although lung transplantation (LTx) improves quality of life and short...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xilong, Maalouf, Naim, Tran, Triet Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624894/
http://dx.doi.org/10.1210/jendso/bvac150.393
_version_ 1784822349036519424
author Li, Xilong
Maalouf, Naim
Tran, Triet Vincent
author_facet Li, Xilong
Maalouf, Naim
Tran, Triet Vincent
author_sort Li, Xilong
collection PubMed
description BACKGROUND: Osteoporosis is a common comorbidity in patients with cystic fibrosis (CF); malabsorption, chronic glucocorticoid use, and chronic inflammation all contribute to increased bone resorption and decreased bone formation. Although lung transplantation (LTx) improves quality of life and short- and long-term outcomes of CF patients, there is little research examining long-term bone health outcomes following LTx in these patients. METHODS: We collected demographic and clinical data on patients who underwent LTx at a single institution between 2006-2019 and had bone mineral density (BMD) measured pre- and post-transplantation. We compared baseline characteristics, long-term BMD trends, and fracture incidence between the two patient populations. We also examined factors associated with post-LTx fractures in CF patients. RESULTS: Charts of 59 LTx recipients were reviewed including 30 with CF and 29 without CF. Compared with non-CF patients, patients with CF were significantly younger (32.8±10.0 vs. 56.7±10.7 years), had lower body mass index (19.7±3.0 vs. 26.7±4.4 kg/m(2)), and significantly lower baseline BMD Z-scores at the lumbar spine (-2.0±1.1 vs. -0.3±1.6), femoral neck (-1.6±0.8 vs. -0.7±1.0), and total hip (-1.6±0.8 vs. -0.7±1.0) (all p<0.001). BMD at all three sites declined significantly in both groups in the first year post-LTx. In subsequent years, and compared with non-CF patients, CF patients exhibited better BMD recovery relative to pre-transplantation, but continued to have lower BMD post-LTx. Post-transplant fractures were relatively common, occurring in 30% and 34% of CF and non-CF patients, respectively. Within the CF group, those who developed fractures after LTx were more likely to have lower baseline BMD T-scores at the femoral neck (p=0.017) and total hip (p=0.050), and lower pre-transplantation percent predicted forced expiratory volume in 1 second (FEV1%) (p=0.042). CONCLUSIONS: Compared with their non-CF counterparts, CF patients undergoing lung transplantation start with significantly lower BMD pre-LTx but exhibit better BMD recovery post-LTx. Despite their younger age at transplantation, CF patients experience a similarly high rate of post-LTx fractures. In CF patients, lower BMD and worse FEV1% pre-LTx are associated with development of post-LTx fractures. These findings highlight the unique contribution of the CF disease process to bone health, as well as a clear need for better prevention and treatment of osteoporosis in CF patients before and after LTx. Presentation: Saturday, June 11, 2022 12:45 p.m. - 1:00 p.m.
format Online
Article
Text
id pubmed-9624894
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96248942022-11-14 OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients Li, Xilong Maalouf, Naim Tran, Triet Vincent J Endocr Soc Bone & Mineral Metabolism BACKGROUND: Osteoporosis is a common comorbidity in patients with cystic fibrosis (CF); malabsorption, chronic glucocorticoid use, and chronic inflammation all contribute to increased bone resorption and decreased bone formation. Although lung transplantation (LTx) improves quality of life and short- and long-term outcomes of CF patients, there is little research examining long-term bone health outcomes following LTx in these patients. METHODS: We collected demographic and clinical data on patients who underwent LTx at a single institution between 2006-2019 and had bone mineral density (BMD) measured pre- and post-transplantation. We compared baseline characteristics, long-term BMD trends, and fracture incidence between the two patient populations. We also examined factors associated with post-LTx fractures in CF patients. RESULTS: Charts of 59 LTx recipients were reviewed including 30 with CF and 29 without CF. Compared with non-CF patients, patients with CF were significantly younger (32.8±10.0 vs. 56.7±10.7 years), had lower body mass index (19.7±3.0 vs. 26.7±4.4 kg/m(2)), and significantly lower baseline BMD Z-scores at the lumbar spine (-2.0±1.1 vs. -0.3±1.6), femoral neck (-1.6±0.8 vs. -0.7±1.0), and total hip (-1.6±0.8 vs. -0.7±1.0) (all p<0.001). BMD at all three sites declined significantly in both groups in the first year post-LTx. In subsequent years, and compared with non-CF patients, CF patients exhibited better BMD recovery relative to pre-transplantation, but continued to have lower BMD post-LTx. Post-transplant fractures were relatively common, occurring in 30% and 34% of CF and non-CF patients, respectively. Within the CF group, those who developed fractures after LTx were more likely to have lower baseline BMD T-scores at the femoral neck (p=0.017) and total hip (p=0.050), and lower pre-transplantation percent predicted forced expiratory volume in 1 second (FEV1%) (p=0.042). CONCLUSIONS: Compared with their non-CF counterparts, CF patients undergoing lung transplantation start with significantly lower BMD pre-LTx but exhibit better BMD recovery post-LTx. Despite their younger age at transplantation, CF patients experience a similarly high rate of post-LTx fractures. In CF patients, lower BMD and worse FEV1% pre-LTx are associated with development of post-LTx fractures. These findings highlight the unique contribution of the CF disease process to bone health, as well as a clear need for better prevention and treatment of osteoporosis in CF patients before and after LTx. Presentation: Saturday, June 11, 2022 12:45 p.m. - 1:00 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9624894/ http://dx.doi.org/10.1210/jendso/bvac150.393 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Bone & Mineral Metabolism
Li, Xilong
Maalouf, Naim
Tran, Triet Vincent
OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients
title OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients
title_full OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients
title_fullStr OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients
title_full_unstemmed OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients
title_short OR01-6 Bone Health Outcomes Post-Lung Transplantation in Cystic Fibrosis Patients
title_sort or01-6 bone health outcomes post-lung transplantation in cystic fibrosis patients
topic Bone & Mineral Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624894/
http://dx.doi.org/10.1210/jendso/bvac150.393
work_keys_str_mv AT lixilong or016bonehealthoutcomespostlungtransplantationincysticfibrosispatients
AT maaloufnaim or016bonehealthoutcomespostlungtransplantationincysticfibrosispatients
AT trantrietvincent or016bonehealthoutcomespostlungtransplantationincysticfibrosispatients